This systematic review reported that the addition of VEGF/VEGFR inhibitors could reduce the incidence of drug-induced ILD at any grade caused by EGFR-TKI in patients with NSCLC, but not of those at grade ≥ 3, although odds ratio varied across clinical studies. Here, VEGFA is linked to interstitial lung disease.